Class action pursued concerning safety defects with GLP-1 drugs Mounjaro, Trulicity, & Zepbound
An application has been filed in Quebec to obtain authorization to institute a class action concerning the drugs Mounjaro, Trulicity, and Zepbound, alleging that the widely used diabetes and weight-loss medications may expose patients to serious health risks that were not adequately disclose…
View the post titled Class action pursued concerning safety defects with GLP-1 drugs Mounjaro, Trulicity, & ZepboundOzempic, a diabetes drug linked to gastrointestinal issues and vision loss, approved to treat kidney issues
Ozempic, a diabetes drug that has been the subject of multiple regulatory investigations due to its potential to expose users to serious health risks (including gastrointestinal issues and vision loss), has been approved to treat a new type of chronic health condition: kidney decline. Ozempi…
View the post titled Ozempic, a diabetes drug linked to gastrointestinal issues and vision loss, approved to treat kidney issuesReceive Blog Posts
By subscribing to our blog, you will receive an email when a new post is added. You can unsubscribe at any time by sending an email to us at [email protected] with the word “unsubscribe” in the subject line.